Tacrolimus (novaliq)

他克莫司 (novaliq)

Report date: 2026/04/04 20:00:24

Base Information

Drug NameTacrolimus (novaliq)
Drug Alias Name他克莫司眼用溶液BTQ2401BTQ-2401NOV05NOV-05
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Molecular Glue
Mechanisms of ActionCalcineurin inhibitorsCytokines inhibitorsImmunosuppressants +[5] 
TargetsCalcineurinFK506-binding protein 1ACytokines +[4] 
Therapy Area/IndicationsUveitis, AnteriorUveitisXerophthalmia +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovaliq Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesNovaliq Gmbh
Inactive CompaniesN/A
Active IndicationsUveitis, AnteriorUveitisXerophthalmia +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A